Dragoni Francesca, Garofalo Maria, Di Gerlando Rosalinda, Rizzo Bartolo, Bordoni Matteo, Scarian Eveljn, Viola Camilla, Bettoni Veronica, Fiamingo Giuseppe, Tornabene Danilo, Scanu Lucia, Pansarasa Orietta, Diamanti Luca, Gagliardi Stella
IRCCS Mondino Foundation, Pavia, Italy.
IRCCS Mondino Foundation, Pavia, Italy; University of Pavia, Pavia, Italy.
Neurobiol Dis. 2025 Mar;206:106823. doi: 10.1016/j.nbd.2025.106823. Epub 2025 Feb 2.
Amyotrophic lateral sclerosis (ALS) is an adult neurodegenerative disorder. According to clinical criteria, ALS patients can be classified into eight subgroups: classic, bulbar, pyramidal, pure lower motor neuron, flail arm, pure upper motor neuron, flail leg, and respiratory. There are no well-established molecular biomarkers for early diagnosis, prognosis, and progression monitoring of this fatal disease. Classification based on clinical phenotypes could be associated with peculiar gene expression patterns shaped during lifespan, allowing the identification of specific sporadic ALS (sALS) subtypes with less heterogeneous clinical and biological features. Our objective was to define a phenotype-specific transcriptomic signature of distinct ALS phenotypes, and lay the foundation for biomarkers development. We characterized 48 sALS patients by clinical and paraclinical parameters, and subdivided them in "Classic" (n = 12), "Bulbar" (n = 10), "Flail Arm" (n = 7), "Flail Leg" (n = 10) and "Pyramidal" (n = 9) phenotypes. RNAs extracted from patients' PBMCs and 19 controls were sequenced. Our analysis allowed the visualization of gene expression differential clusters between patients and controls. Interestingly, only one gene (Y3_RNA, a misc_RNA component of the Ro60 ribonucleoprotein involved in cellular response to interferon-alpha) was upregulated at different levels across all phenotypes, whereas other genes appeared phenotype-specific. The work proposed stress the innovative view of ALS as a multi-systemic disorder rather than a pure motor neuron-associated and 'neurocentric' pathology. The possibility to cluster ALS patients based on their molecular signature pave the way for future personalized clinical trials and early diagnosis.
肌萎缩侧索硬化症(ALS)是一种成人神经退行性疾病。根据临床标准,ALS患者可分为八个亚组:经典型、延髓型、锥体束型、纯下运动神经元型、连枷臂型、纯上运动神经元型、连枷腿型和呼吸型。对于这种致命疾病的早期诊断、预后和病情监测,目前尚无成熟的分子生物标志物。基于临床表型的分类可能与生命周期中形成的特定基因表达模式相关,从而有助于识别临床和生物学特征异质性较小的特定散发性ALS(sALS)亚型。我们的目标是确定不同ALS表型的表型特异性转录组特征,为生物标志物的开发奠定基础。我们通过临床和辅助临床参数对48例sALS患者进行了特征分析,并将他们分为“经典型”(n = 12)、“延髓型”(n = 10)、“连枷臂型”(n = 7)、“连枷腿型”(n = 10)和“锥体束型”(n = 9)表型。从患者外周血单核细胞(PBMC)和19名对照中提取的RNA进行了测序。我们的分析使我们能够观察到患者和对照之间基因表达差异簇。有趣的是,只有一个基因(Y3_RNA,Ro60核糖核蛋白的一种杂项RNA成分,参与细胞对α干扰素的反应)在所有表型中均在不同水平上调,而其他基因则表现出表型特异性。这项工作强调了将ALS视为一种多系统疾病而非单纯运动神经元相关的“神经中心性”病理学的创新观点。根据分子特征对ALS患者进行聚类的可能性为未来的个性化临床试验和早期诊断铺平了道路。